Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial Academic Article Article uri icon

Overview

MeSH Major

  • CA-125 Antigen
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Preoperative Care
  • Tomography, X-Ray Computed

abstract

  • Novartis Pharmaceuticals Corporation.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(14)70030-0

PubMed ID

  • 24556040

Additional Document Info

start page

  • 286

end page

  • 96

volume

  • 15

number

  • 3